AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20332221 — intervention group
Group type: EXPERIMENTAL
Intervention: RUTF
Number of subjects: 451
Study 20332221 — intervention group
Group type: COMPARATOR
Intervention: CSB pre-mix
Number of subjects: 451
Study 17006376 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone protein plus soy lecithin (25 g/day + 20 g/day)
Number of subjects: 25
Study 17006376 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone protein (25 g/day)
Number of subjects: 25
Study 17006376 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy lecithin (20 g/day)
Number of subjects: 25
Study 17006376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 17006376 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone protein plus soy lecithin
Number of subjects: 25
Study 17006376 — intervention group
Group type: COMPARATOR
Intervention: Soy isoflavone protein plus placebo lecithin
Number of subjects: 25
Study 17006376 — intervention group
Group type: COMPARATOR
Intervention: Placebo protein plus soy lecithin
Number of subjects: 25
Study 16282001 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for GPs in the assessment and management of depression
Number of subjects: 30
Study 11980758 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching using a non-contact 1.48 mm wavelength diode laser; study group (n = 52)
Number of subjects: 77
Study 11980758 — intervention group
Group type: COMPARATOR
Intervention: Non-hatching group (n = 44)
Number of subjects: 77
Study 10789186 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-3
Number of subjects: 54
Study 10789186 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 54
Study 10789186 — intervention group
Group type: EXPERIMENTAL
Intervention: CYFRA 21-1
Number of subjects: 54
Study 9139527 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin (800 mg as single dose)
Number of subjects: 100
Study 9139527 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (250 mg/8 h/72 h)
Number of subjects: 100
Study 1871323 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate release formulation (MPH-IR) with a regular dose of 10mg (n=5) and 5mg (n=1) of methylphenidate (MPH) in the first pilot study.
Number of subjects: 12
Study 1871323 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release formulation (MPH-SR) with a regular dose of 20mg of methylphenidate (MPH) in the second pilot study.
Number of subjects: 12
Study 6384510 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 0
Study 6384510 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 6384510 — intervention group
Group type: COMPARATOR
Intervention: Control (group therapy only)
Number of subjects: 0
Study 30978439 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified protocol for hand-mixed GIC Fissure Sealants (FS)
Number of subjects: 0
Study 30978439 — intervention group
Group type: COMPARATOR
Intervention: Original protocol for hand-mixed GIC Fissure Sealants (FS)
Number of subjects: 0
Study 30165479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation + CRT
Number of subjects: 102
Study 30165479 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 102
Study 27357094 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized nutrition advice (level 1, level 2, level 3)
Number of subjects: 1607
Study 27357094 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized nutrition advice (level 3)
Number of subjects: 1607
Study 27357094 — intervention group
Group type: COMPARATOR
Intervention: Conventional dietary advice (control; level 0)
Number of subjects: 1607
Study 25038486 — intervention group
Group type: EXPERIMENTAL
Intervention: Asunaprevir 200mg plus PegIFNα/RBV
Number of subjects: 238
Study 25038486 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus PegIFNα/RBV
Number of subjects: 238
Study 22859321 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate treatment protocol for acute severe asthma exacerbation
Number of subjects: 143
Study 22859321 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol for the initial treatment of acute asthma exacerbation (Control group)
Number of subjects: 143
Study 20301114 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (cisplatin/fluorouracil plus either docetaxel or epirubicin)
Number of subjects: 0
Study 20301114 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (general)
Number of subjects: 0
Study 18358671 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete resection of the great saphenous vein stump with endothelial inversion (Group B)
Number of subjects: 135
Study 18358671 — intervention group
Group type: COMPARATOR
Intervention: Conventional flush ligation at the level of the saphenofemoral junction (Group A)
Number of subjects: 135
Study 16011771 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency electrical pulses (two pulses for subgroups 1A and 2A; four pulses for subgroups 1B and 2B)
Number of subjects: 75
Study 16011771 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency electrical pulses (four pulses for subgroups 1B and 2B)
Number of subjects: 75
Study 16011771 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 teeth) prepared with Hero Shapers and irrigated with 5 mL of EDTA (10%) and 5 mL of 5% NaOCl at 50 degrees C, no electrical pulse treatment
Number of subjects: 75
Study 12452757 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitors (PPIs)
Number of subjects: 0
Study 12452757 — intervention group
Group type: COMPARATOR
Intervention: H2RAs or sucralfate
Number of subjects: 0
Study 10102549 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) using a bioabsorbable membrane
Number of subjects: 14
Study 10102549 — intervention group
Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (CTG)
Number of subjects: 14
Study 10158027 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition (theory-based intervention strategies)
Number of subjects: 128
Study 10158027 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 128
Study 2358942 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium, 550 mg administered 30 minutes postoperatively
Number of subjects: 36
Study 2358942 — intervention group
Group type: COMPARATOR
Intervention: Naproxen sodium, 550 mg administered 30 minutes preoperatively
Number of subjects: 36
Study 582768 — intervention group
Group type: EXPERIMENTAL
Intervention: Suloctidil (Sulocton)
Number of subjects: 0
Study 31992669 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC)
Number of subjects: 69
Study 31992669 — intervention group
Group type: COMPARATOR
Intervention: Large-Volume Nebulization-Based Humidifier
Number of subjects: 69
Study 31009339 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase 0.4 mg/kg
Number of subjects: 348
Study 31009339 — intervention group
Group type: COMPARATOR
Intervention: Alteplase 0.9 mg/kg
Number of subjects: 348
Study 27521828 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief smoking cessation intervention (protocolized counseling, medications, referrals to a quitline)
Number of subjects: 156
Study 27521828 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief smoking cessation intervention
Number of subjects: 156
Study 27521828 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 156
Study 24620920 — intervention group
Group type: EXPERIMENTAL
Intervention: ADV in combination with HB‐110
Number of subjects: 27
Study 24620920 — intervention group
Group type: COMPARATOR
Intervention: ADV alone
Number of subjects: 27
Study 23523455 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS guidance
Number of subjects: 543
Study 23523455 — intervention group
Group type: COMPARATOR
Intervention: Angiography guidance
Number of subjects: 543
Study 23523455 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS guidance (per-protocol analysis)
Number of subjects: 543
Study 23523455 — intervention group
Group type: COMPARATOR
Intervention: Angiography guidance (per-protocol analysis)
Number of subjects: 543
Study 21757932 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 mg/kg)
Number of subjects: 78
Study 21757932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg) injected through the tonsillar capsule
Number of subjects: 78
Study 19337628 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Buscopan (20 mg three times a day, n=37)
Number of subjects: 118
Study 19337628 — intervention group
Group type: EXPERIMENTAL
Intervention: Buscopan Suppository (30 mg once daily, n=21)
Number of subjects: 118
Study 19337628 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Drotaverine (80 mg three times a day, n=30)
Number of subjects: 118
Study 19337628 — intervention group
Group type: COMPARATOR
Intervention: Calcium Gluconate Tablets (one three times a day, n=16)
Number of subjects: 118
Study 19337628 — intervention group
Group type: COMPARATOR
Intervention: Calendula Suppository (once daily, n=14)
Number of subjects: 118
Study 19337628 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Buscopan
Number of subjects: 118
Study 19337628 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal Buscopan
Number of subjects: 118
Study 19337628 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Drotaverine
Number of subjects: 118
Study 16426272 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a history of atopic disorders
Number of subjects: 186
Study 16426272 — intervention group
Group type: COMPARATOR
Intervention: Patients without a history of atopic disorders
Number of subjects: 186
Study 15294401 — intervention group
Group type: EXPERIMENTAL
Intervention: JUST CD
Number of subjects: 62
Study 15294401 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 62
Study 11356239 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nortriptyline (NT) and interpersonal psychotherapy (IPT)
Number of subjects: 140
Study 11356239 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy (either IPT or NT alone)
Number of subjects: 140
Study 11356239 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 140
Study 11356239 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 140
Study 11356239 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment (combined NT and IPT)
Number of subjects: 140
Study 11356239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 8988955 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 60
Study 8988955 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 60
Study 8988955 — intervention group
Group type: COMPARATOR
Intervention: Imipramine to Placebo
Number of subjects: 60
Study 8988955 — intervention group
Group type: COMPARATOR
Intervention: Placebo (originally treated with Phenelzine)
Number of subjects: 60
Study 8067244 — intervention group
Group type: COMPARATOR
Intervention: Oxymetazoline spray
Number of subjects: 25
Study 8067244 — intervention group
Group type: COMPARATOR
Intervention: Oxymetazoline solution
Number of subjects: 25
Study 8067244 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 25
Study 8067244 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 25
Study 3377149 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of 0.075% bupivacaine at a rate of 12‐18 ml/hour
Number of subjects: 73
Study 3377149 — intervention group
Group type: COMPARATOR
Intervention: Intermittent top‐ups of 0.5% bupivacaine
Number of subjects: 73
Study 4890523 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine
Number of subjects: 0
Study 4890523 — intervention group
Group type: COMPARATOR
Intervention: Debrisoquine sulphate
Number of subjects: 0
Study 4890523 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa (high doses)
Number of subjects: 0
Study 31047902 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniMed 640G system with the suspend‐before‐low feature enabled (intervention group)
Number of subjects: 153
Study 31047902 — intervention group
Group type: COMPARATOR
Intervention: MiniMed 640G pump (control group)
Number of subjects: 153
Study 28659138 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA) and intervention before and during chemotherapy
Number of subjects: 0
Study 28659138 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy regimens and standard of care
Number of subjects: 0
Study 28659138 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA) and intervention
Number of subjects: 0
Study 27800649 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin
Number of subjects: 0
Study 27800649 — intervention group
Group type: COMPARATOR
Intervention: liraglutide
Number of subjects: 0
Study 24158583 — intervention group
Group type: EXPERIMENTAL
Intervention: Protecto® sealant
Number of subjects: 40
Study 24158583 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Bond® sealant
Number of subjects: 40
Study 24158583 — intervention group
Group type: COMPARATOR
Intervention: Control (unsealed quadrant)
Number of subjects: 40
Study 21627518 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine HCl (12.5 mg/kg) IV administration
Number of subjects: 8
Study 21627518 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine HCl (12.5 mg/kg) IM administration
Number of subjects: 8
Study 19531212 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (aromatase inhibitor)
Number of subjects: 88
Study 19531212 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (anti-estrogen)
Number of subjects: 88
Study 19531212 — intervention group
Group type: COMPARATOR
Intervention: COX-2 expression
Number of subjects: 88
Study 19531212 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase expression
Number of subjects: 88
Study 17175400 — intervention group
Group type: EXPERIMENTAL
Intervention: Full individualized feedback condition
Number of subjects: 145
Study 17175400 — intervention group
Group type: COMPARATOR
Intervention: Web site access with feedback on stress and coping strategies
Number of subjects: 145
Study 15531673 — intervention group
Group type: EXPERIMENTAL
Intervention: l‐rhamnose (25 g for 28 days)
Number of subjects: 11
Study 15531673 — intervention group
Group type: EXPERIMENTAL
Intervention: lactulose (25 g for 28 days)
Number of subjects: 11
Study 15531673 — intervention group
Group type: COMPARATOR
Intervention: d‐glucose (control)
Number of subjects: 11
Study 11668308 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial-eligible patients (n=197)
Number of subjects: 348
Study 11668308 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial-ineligible patients (n=169)
Number of subjects: 348
Study 11668308 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort (n=348)
Number of subjects: 348
Study 9549960 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 34
Study 9549960 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 34
Study 7877519 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transdermal oestradiol for 3 months
Number of subjects: 34
Study 7877519 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical transdermal oestradiol with medroxyprogesterone acetate for 3 months
Number of subjects: 34
Study 7877519 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 premenopausal women)
Number of subjects: 34
Study 14552308 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (AF) therapy
Number of subjects: 138
Study 29530267 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet CBT (iCBT)
Number of subjects: 89
Study 29530267 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 89
Study 27846824 — intervention group
Group type: EXPERIMENTAL
Intervention: CenteringPregnancy (CP)
Number of subjects: 0
Study 27846824 — intervention group
Group type: COMPARATOR
Intervention: Individual care (Control)
Number of subjects: 0
Study 25498773 — intervention group
Group type: EXPERIMENTAL
Intervention: RDTs with basic training
Number of subjects: 46
Study 25498773 — intervention group
Group type: EXPERIMENTAL
Intervention: RDTs with enhanced training
Number of subjects: 46
Study 25498773 — intervention group
Group type: COMPARATOR
Intervention: Current practice
Number of subjects: 46
Study 23460707 — intervention group
Group type: EXPERIMENTAL
Intervention: Single early intravesical instillation of pirarubicin (THP) 30 mg in 30 mL of saline
Number of subjects: 77
Study 23460707 — intervention group
Group type: COMPARATOR
Intervention: Control group (no THP instillation)
Number of subjects: 77
Study 20529344 — intervention group
Group type: EXPERIMENTAL
Intervention: ProADM or proET1 alone
Number of subjects: 925
Study 20529344 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding proADM alone (or all five biomarkers jointly) to the PSI and CURB65 scores
Number of subjects: 925
Study 20529344 — intervention group
Group type: EXPERIMENTAL
Intervention: Models with biomarkers
Number of subjects: 925
Study 20529344 — intervention group
Group type: EXPERIMENTAL
Intervention: Developed prediction models with biomarkers
Number of subjects: 925
Study 18971890 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anesthesia with 3-6 microg/kg fentanyl and an epidural bolus of 0.33% bupivacaine followed by a continuous perfusion of 0.175% bupivacaine for up to 48 hours after surgery (TEA group)
Number of subjects: 22
Study 18971890 — intervention group
Group type: COMPARATOR
Intervention: Balanced general anesthesia with 7-20 microg/kg fentanyl (GA group)
Number of subjects: 22
Study 16808800 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatain-Ibu Non-adhesive (Coloplast A/S)
Number of subjects: 12
Study 16808800 — intervention group
Group type: COMPARATOR
Intervention: Biatain Non-adhesive (Coloplast A/S)
Number of subjects: 12
Study 14565739 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo care (skin-to-skin)
Number of subjects: 91
Study 14565739 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 91
Study 10902988 — intervention group
Group type: EXPERIMENTAL
Intervention: E supplement (1171 kJ + 12 mg iron)
Number of subjects: 136
Study 10902988 — intervention group
Group type: COMPARATOR
Intervention: M supplement (209 kJ + 12 mg iron)
Number of subjects: 136
Study 10902988 — intervention group
Group type: COMPARATOR
Intervention: S supplement (104 kJ)
Number of subjects: 136
Study 8883529 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 54
Study 8883529 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate
Number of subjects: 54
Study 7966600 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV mutants with mutations in the core promoter
Number of subjects: 57
Study 7966600 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV mutants with mutations in the core promoter alone
Number of subjects: 57
Study 7966600 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV mutants with mutations in the pre-C region
Number of subjects: 57
Study 7966600 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV mutants with mutations in both the core promoter and pre-C region
Number of subjects: 57
Study 7966600 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations in the core promoter
Number of subjects: 57
Study 3619151 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine caudal anaesthesia (n = 47)
Number of subjects: 82
Study 3619151 — intervention group
Group type: COMPARATOR
Intervention: Halothane anesthesia (control group, n = 35)
Number of subjects: 82
Study 3619151 — intervention group
Group type: COMPARATOR
Intervention: Comparison between caudal anaesthesia and halothane anesthesia
Number of subjects: 82
Study 29187694 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/day pitavastatin
Number of subjects: 120
Study 29187694 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/day pitavastatin
Number of subjects: 120
Study 29187694 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/day pitavastatin
Number of subjects: 120
Study 29187694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 27638812 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab + Methotrexate (IFX + MTX)
Number of subjects: 79
Study 27638812 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate + Methylprednisolone (MTX + methylprednisolone)
Number of subjects: 79
Study 25330142 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg/day enteric-coated aspirin tablets for 6 months
Number of subjects: 32
Study 25330142 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg/day enteric-coated aspirin tablets for 6 months
Number of subjects: 32
Study 25330142 — intervention group
Group type: COMPARATOR
Intervention: Immediate postoperative conditions
Number of subjects: 32
Study 23440485 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation of the hepatic branch of the anterior vagus nerve (HB‐AVn)
Number of subjects: 40
Study 23440485 — intervention group
Group type: COMPARATOR
Intervention: Sacrifice of the hepatic branch of the anterior vagus nerve (HB‐AVn)
Number of subjects: 40
Study 21904634 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% NVC-422 topical gel
Number of subjects: 129
Study 21904634 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% NVC-422 topical gel
Number of subjects: 129
Study 21904634 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% NVC-422 topical gel
Number of subjects: 129
Study 21904634 — intervention group
Group type: EXPERIMENTAL
Intervention: NVC-422 topical gel (all doses)
Number of subjects: 129
Study 17998305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel
Number of subjects: 60
Study 17998305 — intervention group
Group type: COMPARATOR
Intervention: Bipolar electrocautery
Number of subjects: 60
Study 16890481 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 58
Study 16890481 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 58
Study 12793550 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-exhaust suits (BES)
Number of subjects: 50
Study 12793550 — intervention group
Group type: COMPARATOR
Intervention: Rotecno occlusive clothing
Number of subjects: 50
Study 11020506 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomcat catheter
Number of subjects: 66